Discussionsaboutthemostappropriatemethodsfortesting the effectiveness and safety of pharmacological intervention for older patients crowded the literature of the past decade, but little action has followed from such a wide discussion.Thenumberofpatientsaged65yearsandolder included in randomized controlled trials raised. However, epidemiological studies have generally demonstrated that thephenotypicemergenceofthenegativeconsequencesof aging occur much later in life, in the eighth and ninth decade. Interestingly, this is the section of the population thatisexperiencingasteepdemographicexpansion,isoften affected by severe comorbidity and disability, is the most eagerconsumerofdrugs,andalsothemostlikelytosuffer fromtheiatrogenicconsequencesofchronictreatmentand polypharmacy (1) .IntheUnitedStates,nearly90%ofpa-tientsover75yearsofagereceiveoneormoremedications, andtheprobabilityofhavingmultipleprescriptionincreases geometricallywithage,severityofillness,andpoorphysicalandcognitivefunction (2) . Therearemanyreasonswhyfrailolderpersonsthatassume multiple drugs are prone to develop iatrogenesis, including drug-druginteractions,reducedphysiologicalreserve,changes inpharmacokinetics,andpoorcompliance(3). Themanagementofcomorbidconditionswithmultiple medications is indeed one of the greatest challenges in geriatrics. The Hippocratic oath "primum non nocere" is translated into the "unchallenged principle" in geriatric medicine:Thenumberofmedicationsshouldbekeptaslow aspossible.However,whenfacingthe"brownbagfullof pills" brought by your patient, deciding which treatment canstayandwhichoneshouldgoischallenging.Ofcourse, onlydrugswithprovenefficacyshouldstay,butthisisalso notaneasydecision.Elderlypatientswithcomorbidity,disability,andpolypharmacyaresystematicallyexcludedfrom clinicaltrials,eventhosetrialsthattestdrugsmostlyusedin thosesameelderlypatientswithcomorbidity,disability,and polypharmacy.Duetothoseexclusioncriteria,thefindings ofthesetrialscannotbeextendedtoourtypicalpatients: Therefore,weareleftwithan"unchallengedprinciple"and impossibledecisions (4, 5) .
We are certainly not the first to denounce this difficult situation.Eminentgeriatricianshavevoicedthatthecurrent practiceproducesanevidence-biasedratherandevidencebased medicine and have called for the conduction of appropriatelydesignedtrialsinvolvingrealgeriatricpatients (6,7 ArecentarticleappearedinThe LancetbySpinewineand colleagues(9)claimsthatinformationtechnologyhasthepotentialtoimproveandrationalizedrugsprescription.Accordingtotheauthors,prescribing"inthefuturecouldusethree cross-linkeddatabases:thepatient'sdrughistory,ascientific druginformationreferenceandguidelinedatabase,andclinicalinformationthatispatientspecific.Integratedprescribing systems offer promise, but tailoring such systems to the unique concerns of the geriatric patient population is warranted" (9) .Indeed,thismayrepresentavaluablealternative torandomizedcontrolledtrials.Thepossibilitiesareextraordinary,onecanthinkofobservationalstudiesoftheriskassociatedwithuseof potassium-sparingdiureticsinpatients withheartfailure(10)oratstudieselucidatingthecomparativesafetyofconventionalandatypicalantipsychoticsforthe treatmentofbehavioraldisturbancesindementia (11) .
Patientsincludedintheseobservationalstudiesarereal, andremarkablyolder,sicker,andlessfunctionalthanthose traditionally enrolled in randomized controlled trials. As such, they provide invaluable information otherwise not available. Geriatric patients residing in the community, in hospital,andinlong-termcarefacilitiescouldbeeasilyenrolled and drug treatment continuously assessed through electronic monitoring for the daily dispensing of medications.Astandardsetofinformationcollectedsystematically inallgeriatricpatientswillcomplementinformationondrug treatmentandallowacontinuousflowofdataonvirtually infinite numbers of patients, highlighting their most clinically relevant medical conditions and drug-related outcomes, over reliable periods of follow-up. Although this informationisextremelyvaluablebyitself,itmayalsolead toidentifyingquestionsthatcanbeaddressedinrandomized controlledtrialsfocusingoncomorbidityandpolypharmacy. Imagineapatientswitharterialhypertension,atrialfibrillation,heartfailure,andcerebrovasculardisease (12) .Accordingtodifferentguidelines,thispatientshouldroutinely receiveanangiotensinconvertingenzyme-inhibitor(oran angiotensin-blockingagent),adiuretic,warfarin,andastatin, andastudycouldanalyzetherisk/benefitoffurtheraddinga beta-blockerforheartfailureand/orheartratecontrol. Basedonthisconsideration,wewouldliketocallfor establishing networks of real and representative geriatric patients,studiedwithcommonassessmentinstrumentsand codified information on medication use. This appears the onlyfeasiblestrategytoaccruetherelevantinformation that can help in difficult decision about optimizing drug treatmentinfrailolderpatientswhileminimizingtheriskof iatrogenesis. This new approach to pharmacoepidemiological research requires innovative methodologies and interdisciplinaryintegrationofmultipleexperts,including geriatricians, pharmacologists, pharmacists, as well as epidemiologists,statisticians,andeconometricians.
